Exploring the Future of ctDNA and Novel Treatment Strategies

Zachary L. Bercu, MD, RPVI, FSIR, explains how the Liberty endovascular robotic system works from the operator’s perspective and what went into becoming its first adopting site.

Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.

Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.

Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.

Melody Rasouli, MD, MBA, FACOG, discusses oncofertility gaps at NCI-designated cancer centers and ways to speed fertility referrals for patients.

Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.

In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.

Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.